Skip to content

To compare the effect of vapour and injection form of Tranexamic acid in the treatment of coughing of blood

Nebulized versus intravenous tranexamic acid for hemoptysis: A randomized controlled trial - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/063698
Enrollment
150
Registered
2024-03-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J988- Other specified respiratory disorders Health Condition 2: J988- Other specified respiratory disorders

Interventions

Intervention1: Nebulized tranexamic acid: Patients who have active hemoptysis will be administered 500 mg of TA mixed with 5ml of distilled water on arrival and three times daily in the nebulization a

Sponsors

Indian council of medical research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients who are above 18 years of age will be recruited in the study

Exclusion criteria

Exclusion criteria: 1.Patients already received tranexamic acid before presenting to the hospital. 2.Intubated patients on mechanical ventilation. 3.Patients with massive life-threatening hemoptysis who need to be immediately shifted for interventional procedures. 4.Patients not giving consent for participation.

Design outcomes

Primary

MeasureTime frame
1.Cessation of bleeding in patients presenting to ED with active hemoptysis at 6 hours after TA administration in both arms 2.Reduction in volume of hemoptysis at 6 h, 12 h, 24 h, 36 h and 48 h after TA administration in both armsTimepoint: 6 hours(h), 12 h, 24 h, 36 h and 48 h after TA administration in both arms

Secondary

MeasureTime frame
1.Need for interventional procedures on ED basis and adverse effects of TA administration during ED stay for 72 hours 2.D-dimer and fibrinogen levels on arrival and at 24 and 48 hours of ED stayTimepoint: 24, 48 and 72 hours

Countries

India

Contacts

Public ContactDr Prakash Ranjan Mishra

AIIMS New Delhi

ranjan.prakashmishra@gmail.com8826118924

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026